Rainbow FY26 net profit rises 15.3% to ₹2,815 million
Rainbow Children's Medicare Limited reported a 15.3% rise in FY26 consolidated net profit to ₹2,815 million, driven by a 12.4% increase in revenue to ₹17,031 million and robust operational metrics. The board recommended a final dividend of ₹3.5 per share, fixed July 21, 2026, as the record date, and approved the re-appointment of Dr. Ramesh Kancharla, Dr. Dinesh Kumar Chirla, and two independent directors.
*this image is generated using AI for illustrative purposes only.
[Rainbow Children's Medicare Limited](rainbow childrens medicare) has reported a 15.3% increase in consolidated net profit to ₹2,815 million for the financial year ended March 31, 2026, compared to ₹2,442 million in the previous year. Revenue from operations for the year rose 12.4% to ₹17,031 million from ₹15,159 million in FY25. The board of directors, in its meeting held on May 23, 2026, approved the audited standalone and consolidated financial results and recommended a final dividend of ₹3.5 per equity share. The company’s strong performance was driven by healthy momentum across operating metrics, including outpatient footfalls, inpatient discharges, and deliveries, alongside the successful commissioning of new facilities in Bengaluru.
Financial Performance
The company’s profitability improved alongside revenue growth. For the full year, total income reached ₹17,469 million, while total expenses stood at ₹13,871 million. Profit before tax for the year was ₹3,582 million. On a standalone basis, net profit for FY26 was ₹2,500 million, with revenue from operations reaching ₹15,457 million. EBITDA for the year rose 11.1% to ₹5,442 million, with an EBITDA margin of 32.0%.
The following table summarizes the key consolidated financial figures for the full year:
| Key Financial Figures (Consolidated) | Year Ended 31 March 2026 (₹ in Million) | Year Ended 31 March 2025 (₹ in Million) |
|---|---|---|
| Revenue from operations | 17,031 | 15,159 |
| Total income | 17,469 | 15,669 |
| Total expenses | 13,871 | 12,369 |
| Profit before tax | 3,582 | 3,300 |
| Profit after tax | 2,815 | 2,442 |
| Earnings per share (Basic) | 27.41 | 23.97 |
Q4 Performance
In the quarter ended March 31, 2026, consolidated net profit stood at ₹782 million, a 38.3% increase from ₹566 million in the same quarter of the previous year. Revenue from operations reached ₹4,599 million, compared to ₹3,701 million year-on-year. EBITDA for the quarter rose 26.1% to ₹1,447 million, with the EBITDA margin expanding to 31.5% from 31.0%. On a standalone basis, net profit for the quarter was ₹593 million on revenue of ₹4,081 million.
| Q4 Key Metrics | Q4 FY26 | Q4 FY25 |
|---|---|---|
| Consolidated Revenue | ₹4,599 million | ₹3,701 million |
| Consolidated Net Profit | ₹782 million | ₹566 million |
| EBITDA | ₹1,447 million | ₹1,147 million |
| EBITDA Margin | 31.5% | 31.0% |
| Standalone Revenue | ₹4,081 million | — |
| Standalone Net Profit | ₹593 million | — |
Operational Highlights
The company maintained robust operational metrics during the year. Capacity beds increased 23% to 2,375, while operational beds grew 10% to 1,677. Occupancy for the year stood at 46.26%. Inpatient discharges rose 6% to 104,514, and outpatient consultations increased 12% to 15,98,970. Deliveries for the year reached 19,228. The Average Revenue Per Occupied Bed (ARPOB) improved 11% to ₹60,141, while the Average Length of Stay (ALOS) decreased to 2.71 days from 2.85 days in the previous year.
Dividend and Appointments
The board has recommended a final dividend of ₹3.5 per equity share, representing 35% on a face value of ₹10 per share for FY26. The total dividend payout aggregates to ₹355.5 million. The record date for determining eligibility has been fixed as July 21, 2026, and the payment is subject to shareholder approval at the 28th Annual General Meeting scheduled for July 29, 2026.
The board approved the re-appointment of Dr. Ramesh Kancharla as Chairman and Managing Director and Dr. Dinesh Kumar Chirla as Whole Time Director for a period of five years from August 11, 2026. Additionally, Mr. Santanu Mukherjee and Ms. Sundari R. Pisupati were re-appointed as Independent Directors for second terms of five years each. M/s. Lavanya & Associates LLP were re-appointed as Cost Auditors for FY27.
Historical Stock Returns for Rainbow Childrens Medicare
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -0.37% | +1.03% | +4.34% | +1.50% | -0.36% | +199.87% |
What are the company's capital expenditure plans for FY27 to further expand capacity beyond the new Bengaluru facilities?
Will the recent commissioning of new facilities in Bengaluru sustain the current EBITDA margin levels in the coming fiscal year?
How does Rainbow Children's Medicare plan to manage the potential rise in operational costs associated with the 23% increase in capacity beds?
15
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
